Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods
| Autor: | Vandita Johari, Kristi J. Smock, George M. Rodgers, Peter J. Saunders |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Blood Platelets
Ticlopidine Genotyping Techniques Platelet Function Tests Biological Availability CYP2C19 Pharmacology P2Y12 medicine Humans Platelet Prodrugs cardiovascular diseases Active metabolite Biotransformation Genetic testing medicine.diagnostic_test business.industry Hematology Prodrug Clopidogrel Receptors Purinergic P2Y12 Cytochrome P-450 CYP2C19 Purinergic P2Y Receptor Antagonists Aryl Hydrocarbon Hydroxylases Drug Monitoring business Platelet Aggregation Inhibitors circulatory and respiratory physiology medicine.drug |
| Zdroj: | American journal of hematology. 86(12) |
| ISSN: | 1096-8652 |
| Popis: | Clopidogrel is a widely used antiplatelet agent that irreversibly inhibits platelet P2Y12 ADP receptors after conversion to an active metabolite. There are a number of laboratory tests capable of detecting clopidogrel-induced platelet inhibition and published literature correlates suboptimal clopidogrel response to adverse cardiovascular outcomes. Genetic polymorphisms are thought to affect conversion of the prodrug to the active metabolite, and the FDA has recently added a black-box warning to clopidogrel to highlight the effects of these polymorphisms on drug bioavailability and to inform prescribers about the availability of genetic testing. For these reasons, there is growing interest in the use of laboratory tests to monitor patients treated with clopidogrel. This article summarizes the currently available laboratory testing, including platelet function tests and genotyping for CYP2C19 variants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text